Biohaven fuels up for post-Pfizer future with $302M fundraising, fresh faces in the C-suite

A new, slimmed-down Biohaven issued its debut earnings release post-Pfizer split, touting a $301.9 million fundraising, new executive staffers and a pipeline stocked with therapies to test in epilepsy and neuropsychiatric conditions.